Keystone XL Pipeline Clears Major Regulatory Hurdle
High near 64 Monday in Oklahoma City, warm week ahead
Volvo to sell thousands of self-driving cars to Uber
AT&T confident court will reject Justice Department challenge to Time Warner deal
Yellen to step down from Federal Reserve board
Stock'S Earning Overview Ocular Therapeutix, Inc. (OCUL)
17 July 2017, 08:34 | Jan Cross
Other large investors have also recently modified their holdings of the company. State Street Corp raised its stake in shares of OcularTherapeutix by 21.8% in the fourth quarter. Cantor Fitzgerald analyst E. Piros now expects that the biopharmaceutical company will post earnings per share of ($2.09) for the year, up from their prior forecast of ($2.63). Renaissance Technologies LLC acquired a new stake in OcularTherapeutix during the fourth quarter valued at approximately $1,214,000. Wellington Management Group LLP boosted its position in shares of OcularTherapeutix by 35.2% in the first quarter. Parametric Portfolio Associates LLC now owns 30,582 shares of the biopharmaceutical company's stock worth $284,000 after buying an additional 401 shares during the last quarter. Janney Montgomery Scott LLC bought a new stake in shares of OcularTherapeutix during the first quarter worth about $110,000. Berson & Corrado Investment Advisors LLC now owns 32,805 shares of the biopharmaceutical company's stock worth $304,000 after buying an additional 1,785 shares during the last quarter. The institutional investor owned 87,046 shares of the biopharmaceutical company's stock after buying an additional 17,445 shares during the period.
Research professionals at Morgan Stanley now has a $8 target on OcularTherapeutix (NASDAQ:OCUL). (NASDAQ:OCUL) has gone stronger by 29.45%. The firm's 50-day moving average is $10.44 and its 200 day moving average is $8.94.
OcularTherapeutix, Inc. has a one year low of $4.04 and a one year high of $11.91. The company has market cap of $174.77 million.
OcularTherapeutix (NASDAQ:OCUL) last issued its quarterly earnings data on Friday, May 5th. The biopharmaceutical company reported ($0.58) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.48) by $0.10. The Return on Equity ratio of OcularTherapeutix, Inc. According to these analysts, the Low Revenue Estimate for OcularTherapeutix, Inc.is 450 Million and the High Revenue Estimate is 520 Million.
ILLEGAL ACTIVITY WARNING: This news story was first reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this article on another domain, it was stolen and republished in violation of U.S. & global copyright law.
Insider Trades for OcularTherapeutix, Inc. show that the latest trade was made on 14 Dec 2016 where Sawhney (Amarpreet), the Chief Executive Officer completed a transaction type "Buy" in which 45300 shares were traded at a price of $7.85. Morgan Stanley upgraded the shares of OCUL in report on Thursday, February 18 to "Overweight" rating. However, on July 6, 2017, an article published by Seeking Alpha claimed that OcularTherapeutix's management had been misleading investors about manufacturing issues. Analysts have a mean recommendation of 2.80 on this stock (A rating of less than 2 means buy, "hold" within the 3 range, "sell" within the 4 range, and "strong sell" within the 5 range). At the time of writing, Shares the company recently traded 64.73% away 52-week low and noted price movement -44.11% away from the 52-week high level. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and four have assigned a buy rating to the company's stock. OcularTherapeutix now has a consensus rating of "Hold" and a consensus price target of $21.55.
Several analysts have released their opinion on OcularTherapeutix, Inc. The Firm is focused on the development and commercialization of therapies for diseases and conditions of the eye using its hydrogel platform technology.
Driver Charged In Deadly Grand Central Parkway Crash
Another passenger, 33-year-old Layon Campbell, also from Brooklyn, would later die at a hospital, police said. The crash happened at about 6:30 on the eastbound Grand Central Parkway near 188th Street in Jamaica Estates.
Meter-taxi operators attacking Uber drivers
Uber launched their hailing service in South Africa in 2013, attracting thousands of people to their application. Ndou said the meter taxi operators complained that it seemed Uber could do as it pleased.
Procter & Gamble Company (NYSE:PG)
The Company operates through five segments: Beauty; Grooming; Health Care; Fabric & Home Care, and Baby, Feminine & Family Care. Following the transaction, the insider now directly owns 43,608 shares of the company's stock, valued at $3,808,722.72.